[Efficacy of vaccination against hepatitis A in HIV infected adults from Lodz region--preliminary report].
OBJECTIVE
To estimate the prevalence of anti-HAV-T in the group of HIV-positive adults and to assess the efficacy of vaccination against viral hepatitis A.


METHODS
In HIV-infected outpatients anti-HAV-T was determined (electrochemiluminescence method). Patients susceptible to HAV infection were qualified for vaccination.


RESULTS
In the group of 175 HIV-infected patients, 70 persons (40%) were anti-HAV-T positive. Prevalence of anti-HAV-T was significantly higher in patients over 35 years of age. Anti-HAV-T were present in all individuals older than 50 years. So far 47 patients have completed vaccination. Good response (detectable anti-HAV-T 1 month after booster dose) was obtained in 73,0% patients. Individuals with actual CD4 count above 200 cells/ul responded better (81,2%) than persons with CD4 count 200 cells/ul or lower (20%). Nadir CD4 count above 50 cells/ul predicted better response than 50 cells/ul or below (78,8% and 25% respectively). One year after vaccination anti-HAV-T were still detectable in 21 patients (56,8%).


CONCLUSIONS
1. Most of studied HIV-positive patients (60%) were susceptible to HAV infection and should be vaccinated. 2. Good response to vaccination was obtained in 73% of patients and it was higher in persons with actual CD4 count above 200 cells/ul and nadir CD4 count above 50 cells/ul.
Jabłonowska
Elzbieta
E
Klinika Chorób Zakaźnych i Hepatologii, Uniwersytetu Medycznego w Lodzi. lodzemej@tlen.pl
Kuydowicz
Jan
J
Małolepsza
Ewa
E
D000328:Adult; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D006506:Hepatitis A / Q000517:prevention & control*; D035922:Hepatitis A Antibodies / Q000096:biosynthesis* / Q000097:blood; D022362:Hepatitis A Vaccines / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011044:Poland / Q000453:epidemiology; D015995:Prevalence; D012720:Severity of Illness Index; D014779:Virus Replication / Q000187:drug effects
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines